A 48-year-old woman with metastatic colorectal cancer has completed 2 cycles of 5-fluorouracil (5-FU) and leucovorin. She now presents with severe hand-foot syndrome (palmar-plantar erythrodysesthesia), grade 3 diarrhea, and oral ulceration. Her performance status has declined. The oncologist is considering whether to continue, modify, or switch chemotherapy. What is the most appropriate immediate next step?

Explanation

## Management of 5-Fluorouracil Toxicity ### Clinical Context The patient has developed grade 3 hand-foot syndrome and grade 3 diarrhea—both dose-limiting toxicities of 5-FU. These are not idiosyncratic reactions but predictable, dose-dependent adverse effects that require immediate intervention to prevent progression to life-threatening complications (e.g., toxic megacolon, severe dehydration). ### Correct Management Strategy **Key Point:** When grade 3 or higher toxicity occurs during 5-FU therapy, the standard approach is: 1. **Hold the current cycle** to allow recovery of affected tissues 2. **Provide aggressive supportive care** (hydration, antidiarrheals, topical care for hand-foot syndrome) 3. **Reassess after recovery** for dose modification (typically 20–25% reduction), schedule change, or alternative regimen 4. **Resume treatment only when toxicity has resolved** to grade ≤1 **High-Yield:** 5-FU toxicity is reversible if caught early and managed appropriately. Continuing full-dose therapy in the face of grade 3 toxicity risks cumulative organ damage and treatment abandonment due to intolerable side effects. ### Mechanism of 5-FU Toxicity **Clinical Pearl:** 5-FU is metabolized to active metabolites (FdUMP, FdUTP) that inhibit thymidylate synthase and incorporate into RNA/DNA. Hand-foot syndrome results from prolonged exposure of palmar and plantar skin to these metabolites; diarrhea reflects mucosal damage in the GI tract. Both are exacerbated by dose and infusion duration. **Mnemonic: HOLD-SUPPORT-REASSESS** — **H**old the drug, **O**ral/topical care, **L**iquids/antidiarrheals, **D**ocument recovery; **S**upport with emollients, **U**rinalysis, **P**erfusion status, **P**ain control, **O**ral hygiene, **R**eassess after 1–2 weeks, **T**hen dose-reduce or reschedule. ### Table: 5-FU Toxicity Grading and Management | Toxicity | Grade 1–2 | Grade 3 | Grade 4 | | --- | --- | --- | --- | | Hand-foot syndrome | Continue, topical care | Hold, reassess | Hold, consider discontinue | | Diarrhea | Continue, antidiarrheals | Hold, IV fluids | Hold, ICU support | | Mucositis | Continue, oral care | Hold, supportive care | Hold, TPN if severe | | Next action | Dose reduction optional | Dose reduction 20–25% | Discontinue or major modification | ### Why Not the Other Options **Option 0 (Oxaliplatin monotherapy):** Oxaliplatin is a platinum agent, not an antimetabolite, and is used in combination with 5-FU (FOLFOX), not as monotherapy for metastatic colorectal cancer. Removing 5-FU reduces efficacy. **Option 2 (Increase leucovorin):** Leucovorin enhances 5-FU efficacy but does not reduce toxicity; in fact, higher leucovorin may worsen GI toxicity. This approach is contraindicated. **Option 3 (Switch to capecitabine):** Capecitabine is an oral prodrug of 5-FU that is metabolized to the same active metabolites. It carries the same toxicity profile and is not a solution for acute 5-FU toxicity. Switching during active toxicity is inappropriate.